CB Insights
Technology Market Intelligence
Technology Market Intelligence
US Stem Cell is a biotechnology company focused on the discovery, development, and commercialization of cell therapies for the treatment of chronic and acute heart damage.
Company (IPO / Went public)
Phone: 954-835-1500
1560 Sawgrass Corporate Parkway
4th Floor
Sunrise, 33323
Florida, United States
| Total Funding | Date of Last Funding | |
|---|---|---|
| US Stem Cell | $43M | Feb 20, 2008 |
| See all 15 competitors | ||
| Per Week | Per Month | Per 6 Months | Per Year | |
|---|---|---|---|---|
| Rank | Login to see details | |||
| Page Views Per Million | Login to see details | |||
| Page Views Per User | Login to see details | |||
| Reach Per Million | Login to see details | |||
| Company | Status | Description | Investors |
|---|---|---|---|
| Chapel Hill, North Carolina, United States | Acquired | Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of technologies for disease areas where current therapies don't exist, are ineffective or are inadequate. Cardioxyl has developed solutions in the chemistry, biology and clinical applications of nitroxyl technology. The company's core nitroxyl platform has generated several pre-clinic...Show all | Login to see details |
| British Columbia, Canada | Alive / Active | Inflazyme Pharmaceuticals Ltd. is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs. | Login to see details |
| Title | Application Date | Patent Date | Status (Patent / Application) |
|---|---|---|---|
| Method of enhancing myogenesis by electrical stimulation | Mar 28, 2005 | Jan 27, 2009 | Patent |
